CD25-Targeted Aptamer–Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies

<b>Background</b>: CD25, the α-chain of the interleukin-2 (IL-2) receptor, is highly expressed on malignant cells and tumor-infiltrating regulatory T-cells (Tregs) in hematologic malignancies, making it an attractive therapeutic target for tumor elimination and immunomodulation. <b>Methods</b>: We d...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Sanghyeok Woo, Ju-Hyung Kang, Inu Song, Soryong Lim, Hwarim Ryu, Yujin Lee, Daekyun Lee
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2026-02-01
Sarja:	Pharmaceutics
Aiheet:	aptamer aptamer–drug conjugate CD25 SELEX targeted therapy hematologic malignancies
Linkit:	https://www.mdpi.com/1999-4923/18/2/217
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!